Is the European Medical Products Authorisation Regulation Equipped to Cope with the Challenges of Nanomedicines?

Law and Policy

Volumn 33, Issue 2, 2011, Pages 276-303

  Dorbeck Jung, Bärbel R ^a   Chowdhury, Nupur ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952380555     PISSN: 02658240     EISSN: 14679930     Source Type: Journal    
DOI: 10.1111/j.1467-9930.2011.00339.x     Document Type: Article

References (77)

1. Abraham, John, and Graham Lewis 2000. Regulating Medicines in Europe: Competition, Expertise and Public Health. London: Routledge.
2. Adler, Emanuel. 2002. "Constructivism and International Relations Theory." In Handbook of International Relations, edited by Walter Carlsnaes, Thomas Risse, and Beth Simmons, 95-118. London: Sage Publications.
3. Altenstetter, Christa. 2003. "EU and Member State Medical Devices Regulation, " International Journal of Technology Assessment in Health Care 19: 228-48.
4. Altenstetter, Christa, and Govin Permanand 2006. "EU Regulation of Medical Devices and Pharmaceuticals in Comparative Perspective, " Paper presented at the ECPR/CRI Conference "Frontiers of Regulation, " Bath, UK.
5. Berger, Peter L. 1991. The Social Construction of Reality. London: Penguin Books.
6. Bhogal, Nirmala. 2009. "Regulatory and Scientific Barriers to the Safety Evaluation of Medical Nanotechnologies, " Nanomedicine 4: 495-98.
7. Black, Julia. 2002. "Critical Reflections on Regulation, " Australian Journal of Legal Philosophy 27: 1-35.
8. Broscheid, Andreas, and Jürgen Feick 2005. "Towards a European FDA? The Review of European Phamaceuticals Authorization." Paper presented at the European Union Studies Association Biennial Conference, March 31-April 2, Austin, TX.
9. Brunnée, Jutta, and Stephen J. Toope 2000. "International Law and Constructivism: Elements of an International Theory of International Law, " Columbia Journal of Transnational Law 39 (1): 19-74.
10. Chan, Vivian S. W. 2006. "Nanomedicine: An Unresolved Regulatory Issue, " Regulatory Toxicology and Pharmacology 46: 218-24.
11. Checkel, Jeffrey T. 2001. "The Europeanization of Citizenship." In Transforming Europe: Europeanization and Domestic Change, edited by Maria Cowles, James Caporaso, and Thomas Risse, 180-97. Ithaca, NY: Cornell Univ. Press.
12. Chaudhry, Quasim, C. George, P. Floyd, J. Blackburn, R. Aitken, T. Nwaogu, and A. Boxall 2006. A Scoping Study to Identify Regulatory Gaps for the Products and Applications of Nanotechnologies, Sand Hutton, York, UK: Central Science Laboratory.
13. Chowdhury, Nupur. 2010. "Regulation of Nanomedicines in the EU: Distilling Lessons from the Pediatric and the Advanced Therapy Medicinal Products Approaches, " Nanomedicine 5: 135-42.
14. Committee to Review the National Nanotechnology Initiative. 2006. A Matter of Size. Washington DC: The National Academic Press.
15. Day, Emily S., Lissett R. Bickford, John H. Slater, Nicholas S. Rigall, Rebekah A. Drezek, and Jennifer L. West 2010. "Antibody-Conjugated Gold-Gold Sulfide Nanoparticles as Multifunctional Agents for Imaging and Therapy of Breast Cancer, " International Journal of Nanomedicine 5: 445-54.
16. De Búrca, Grainne, and Joanne Scott (eds.). 2006. Law and New Governance in the EU and the US. Oxford: Hart Publishing.
17. Delogu, Bernardo. 2009. "The Role of EU Scientific Committees for Risk Assessment of Nanomaterials." Paper presented at the Scientific Hearing on Risk Assessment of Nanotechnologies, September 10, Brussels.
18. Dorbeck-Jung, Bärbel R. 2007. "What Can Prudent Public Regulators Learn from the United Kingdom Government's Nanotechnological Regulatory Activities, " Nanoethics 1: 257-70.
19. Dorbeck-Jung, Bärbel R. 2009. "Governing Nanomedicine: Learning from Regulatory Deficiencies of European Medical Technology Regulation, " Politeia 94: 41-57.
20. Dorbeck-Jung, Bärbel R., and Mirjan Oude Vrielink 2007. "European Ways of Governing the Marketing of Pharmaceuticals-A Shift Towards More Integration, Better Consumer Protection and Better Regulation?" In European Ways of Law, edited by Volker Gessner and David Nelken, 279-304. Oxford: Hart Publishing.
21. European Commission. 2000. "Communication from the Commission on the Precautionary Principle." Brussels: COM.
22. European Commission. 2001. "European Governance, " White Paper 428, Brussels: COM.
23. European Group of Ethics in Science and New Technologies. 2007. Opinion on the Ethical Aspects of Nanomedicine. Brussels: European Commission.
24. European Medicines Agency. 2006. "Nanotechnology-Based Medicinal Products for Human Use, " Reflection Paper EMA/CHMP/79769/2006. London: EMA.
25. European Medicines Agency. 2010. "The European Medicines Agency Road Map to 2015: The Agency's Contribution to Science, Medicines, Health, " Draft for Public Consultation EMA/299895/2009. London: EMA.
26. European Science Foundation. 2005. ESF Forward Look on Nanomedicine. Strasbourg Cedex: ESF. (accessed January 9, 2010).
27. European Technology Platform on Nanomedicine. 2006. Nanomedicine. Nanotechnology for Health, Strategic Research Agenda for Nanomedicine. Tyndall National Institute, University College, Cork, Ireland.
28. European Technology Platform on Nanomedicine. 2009. Roadmaps in Nanomedicine Toward 2020. Berlin: ETP. (accessed April 9, 2010).
29. Everson, Michelle, and Ellen Vos (eds.). 2009. Uncertain Risks Regulated. Oxon, UK: Routledge-Cavendish.
30. Feick, Jürgen. 2002. Regulatory Europeanization, National Autonomy and Regulatory Effectiveness: Marketing Authorization for Pharmaceuticals: Max-Planck-Institute for the Study of Societies Discussion Papers, No. 6. Köln: Max-Planck-Institute for the Study of Societies.
31. Feick, Jürgen. 2005. "Learning and Interest Accommodation in Policy and Institutional Change: EC Risk Regulation in the Pharmaceuticals Sector, " CARR Discussion Paper Series, No 25. London: London School of Economics and Political Science.
32. Finnemore, Martha J., and Stephen Toope 2001. "Alternatives to 'Legalization': Richer Views of Law and Politics, " International Organization 55: 743-58.
33. Freeman, Edward. 1983. "Stockholders and Stakeholders: A New Perspective on Corporate Governance. California Management Review 25: 88-106.
34. Furgeson Darin Y. 2008. Nanotools for Toxicity Assessments of Nanomedicines. 22 July. Rockville, MD: U.S. Food and Drug Administration. (accessed August 9, 2009).
35. Gaspar, Rogério. 2007. "Regulatory Issues Surrounding Nanomedicines: Setting the Scene for the Next Generation of Nanopharmaceuticals, " Nanomedicine 2: 143-47.
36. Gaspar, Rogério S., and Ruth Duncan 2009. "Polymeric Carriers: Preclinical Safety and the Regulatory Implications for Design and Development of Polymer Therapeutics, " Advanced Drug Delivery Reviews 61: 1220-31.
37. Geertsma, Robert E., A. C. P. de Bruijn, E. S. M. Hilbers-Modderman, M. L. Hollestelle, G. Bakker, and B. Roszek 2007. New and Emerging Medical Technologies: A Horizon Scan of Opportunities and Risks. February 2. Bilthoven: RIVM (Dutch Institute for Public Health and the Environment). (accessed July 9, 2010).
38. Giddens, Anthony. 1984. The Constitution of Society. Cambridge: Polity Press.
39. Green Cowles, Maria. 2003. "Non-State Actors and False Dichotomies: Reviewing RI/IPE Approaches to European Integration, " Journal of European Public Policy 10: 102-20.
40. Hansen, Steffen. 2009. "Regulation and Risk Assessment of Nanomaterials-Too Little, Too Late." PhD diss., Technical University of Denmark.
41. Hanson, David. 2005. CE Marking. Product Standards and World Trade. Cheltenham, UK: Edward Elgar.
42. Hart, Dieter, and Norbert Reich 1990. Integration und Recht des Arzneimittelmarktes in der EG. Baden-Baden: Nomos.
43. Hood, Christopher, Henry Rothstein, and Robert Baldwin 2001. The Government of Risk: Understanding Risk Regulation Regimes. Oxford: Oxford Univ. Press.
44. International Risk Governance Council. 2006. White Paper on Nanotechnology Risk Governance. Geneva: IRGC. (accessed April 9, 2010).
45. de Jong, Wim H., and Paul Borm 2008. "Drug Delivery and Nanoparticles: Applications and Hazards, " International Journal of Nanomedicine 3: 133-49.
46. de Jong, Wim H., Bert Roszek, and Robert E. Geertsma 2005. Nanotechnology in Medical Applications: Possible Risks for Human Health. Bilthoven: RIVM. (accessed July 12, 2010).
47. Kagan, Valerie E., Hülya Bayir, and Anna A. Shvedova 2005. "Nanomedicine and Nanotoxicology: Two Sides of the Same Coin, " Nanomedicine: Nanotechnology, Biology and Medicine 1: 313-16.
48. Kandlikar, Milind, Gurumurthy Ramachandran, Andrew D. Maynard, etal. (2007) "Health Risk Assessment for Nanoparticles: A Case for Using Expert Judgement, " Journal of Nanoparticle Research 9: 137-56.
49. Kent, Julie, Alex Faulkner, Ingrid Geesink, and Donald FitzPatrick 2006. "Towards Governance of Human Tissue Engineered Technologies in Europe: Framing the Case for a New Regulatory Regime, " Technological Forecasting and Social Change 73: 41-60.
50. Koslowski, Rey. 1999. "A Constructivist Approach to Understanding the European Union as a Federal Polity, " Journal of European Public Policy 6: 561-78.
51. Linkov, Igor, F. Kyle Satterstrom, and Lisa M. Corey 2008. "Nanotoxicology and Nanomedicine: Making Hard Decisions, " International Journal of Nanomedicine 4: 167-71.
52. Mehta, Michael D. 2004. "The Future of Nanomedicine Looks Promising, But Only if We Learn from the Past, " Health Law Review 13: 16-18.
53. Miller, Sonia E. 2007. "Regulating Nanotechnology: A Viscous Circle." In Nanoscale: Issues and Perspectives for the Nano Century, edited by Nigel M. de S. Cameron, and M. Ellen Mitchell, 155-77. Chicago: Wiley InterScience.
54. National Institute for Occupational Safety and Health. 2009. Approaches to Safe Nanotechnology. Atlanta, GA: NIOSH. (accessed April 9, 2010).
55. Nel, Andre, Tian Xia, Lutz Madler, and Ning Li 2006. "Toxic Potential of Materials at the Nanolevel, " Science 311: 622-27.
56. Papaluca-Amati, M. 2008. "Safety for Success." Presentation at the 2nd Annual Nanotechnology Workshop, Brussels, October 3, 2008, .
57. Park, Margriet V. D. Z., Daniëlle P. K. Lankveld, Henk van Loveren, and Wim H. de Jong 2009. "The Status of in Vitro Toxicity Studies in the Risk Assessment of Nanomaterials, " International Journal of Nanomedicine 4: 669-85.
58. Poland, Craig A., Rodger Duffin, Ian Kinloch, Andrew Maynard, William A. H. Wallace1, Anthony Seaton, Vicki Stone, Simon Brown, William MacNee1, and Ken Donaldson 2008. "Carbon Nanotubes Introduced into the Abdominal Cavity Display Asbestos-Like Pathogenic Behaviour in a Pilot Study, " Nature Nanotechnology 3: 423-28.
59. Royal Commission on Environmental Pollution. 2008. Novel Materials in the Environment: The Case of Nanotechnology. London: RCEP. (accessed April 9, 2010).
60. Royal Society and Royal Academy of Engineering. 2004. Nanoscience and Nanotechnologies: Opportunities and Uncertainties. London: RS/RAE. (accessed April 9, 2010).
61. Rothstein, Henry. 2009. "The Origins of Regulatory Uncertainty in the UK Food Safety Regime." In Uncertain Risks Regulated, edited by Michelle Everson and Ellen Vos, 69-85. Oxon, UK: Routledge-Cavendish.
62. Sadrieh, Nakissa. 2005. "FDA Considerations for Regulation of Nanomaterial Containing Products." Paper presented at the Conference on "Nanotechnology: Impact on Health and Regulation of the Medicines and Health Products Regulatory Agency", United Kingdom.
63. Sanhai, Wendy R., Jason H. Sakamoto, Richard Canady, and Mauro Ferrari 2008. "Seven Challenges for Nanomedicine, " Nature Nanotechnology 3: 242-44.
64. Scientific Committee on Emerging and Newly Identified Health Risks. 2007. Opinion on the Appropriateness of the Risk Assessment Methodology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials. Brussels: DG Health and Consumers.
65. Scientific Committee on Emerging and Newly Identified Health Risks. 2008. Opinion on the Scientific Aspects of the Existing and Proposed Definitions Relating to Products of Nanoscience and Nanotechnologies. Brussels: DG Health and Consumers.
66. Scientific Committee on Emerging and Newly Identified Health Risks. 2010. Opinion on the Scientific Basis for the Definition of the Term "Nanomaterial." Brussels: DG Health and Consumers.
67. Scott, Colin. 2002. "Private Regulation of the Public Sector: A Neglected Facet of Contemporary Governance, " Journal of Law and Society 29: 56-76.
68. Senden, Linda. 2004. Soft Law in European Community Law. Oxford: Hart Publishing.
69. TriMark Publications. 2008. Medical Nanotechnology Markets. New York: TriMark Publications.
70. Trubek, David M., Patrick Cottrell, and Mark Nance 2006. "Soft Law, Hard Law and EU Integration." In Law and New Governance in the EU and the US, edited by Grainne de Burca and Joanne Scott, 65-94. Oxford: Hart Publishing.
71. Valverde, José Luis. 2007. "Toward a Global Legal Statute for Medicinal Products, " Pharmaceutical Policy and Law 9: 273-315.
72. Vogel, David. 2003. "The New Politics of Risk Regulation in Europe, " Yearbook of European Environmental Law 3: 1-42.
73. Vos, Ellen. 2004. Overcoming the Crisis of Confidence: Risk Regulation in an Enlarged European Union. Maastricht, the Netherlands: Unigraphic.
74. Wagner, Volker, Anwyn Dullaart, Anne-Katrin Bock, and Axel Zweck 2006. "The Emerging Nanomedicine Landscape, " Nature Biotechnology 24: 1211-17.
75. Wilson, R. F. 2006. "Nanotechnology: The Challenges of Regulating Known Unknowns, " Journal of Law Medicine & Ethics 34: 704-13.
76. van Zijverden, Maaike, and Adrienne M. Sips (eds.). 2008. Nanotechnology in Perspective: Risks for Man and the Environment. Bilthoven, the Netherlands: RIVM.
77. Zu, Yuangang, Yu Zhang, Xiuhua Zhao, Qi Zhang, Yang Liu, and Ru Jiang 2009. "Optimization of the Preparation Process of Vinblastine Sulfate (VBLS)-Loaded Folate-Conjugated Bovine Serum Albumin (BSA) Nanoparticles for Tumor-Targeted Drug Delivery Using Response Surface Methodology (RSM), " International Journal of Nanomedicine 4: 321-33.